AI MARKET SCANNING

Cue Biopharma Inc

📅 Next Catalyst: Nov 12, 2026 (🌙 Close) 🏛️ NASDAQ 📁 Health Technology 🏭 Biotechnology
AVG HISTORICAL GAP +0.46%
MAX GAP RECORD -4.81%
🔒 PRO INSTITUTIONAL AI PREDICTIVE WIN RATE
94.2%
REVEAL PRO DIRECTION ⚡

SENTINEL HISTORICAL GAP VIEWER

// $CUE
📊 1-YEAR TIMELINE (GAPS PLOTTED) 🔮 SIMULATE SETUP 🔒
Bullish Opening Gap Bearish Opening Gap T-1 Close Baseline

CATALYSTS & GAP HISTORY

Nov 12, 2026 Earnings Release 2026-11-12 (UNDETERMINED) 🔮 UPCOMING 🔒
Aug 18, 2026 Earnings Release 2026-08-18 (AFTER CLOSE)
+2.96%
May 13, 2026 Earnings Release 2026-05-13 (AFTER CLOSE)
-0.88%
Mar 16, 2026 Earnings Release 2026-03-16 (AFTER CLOSE)
-4.81%
Nov 12, 2025 Earnings Release 2025-11-12 (AFTER CLOSE)
-0.45%
Aug 12, 2025 Earnings Release 2025-08-12 (AFTER CLOSE)
+2.53%
May 12, 2025 Earnings Release 2025-05-12 (AFTER CLOSE)
-2.80%
Nov 14, 2024 Earnings Release 2024-11-14 (AFTER CLOSE)
+0.00%

VOLATILITY & GAP BIAS

AVG GAP MOVE 2.3%
Bullish Gaps (5)
Bearish Gaps (2)
Neutral / Flat (3)

QUANTITATIVE LIVE RADAR BLOTTER

Algorithmic execution stream for $CUE

EXECUTIONS0 LOGS
STATUS🔒 ENCRYPTED
Execution Date Strategy & Setup Direction Execution Range Hold Time Net PnL
Radar monitoring: awaiting next setup.
🔒 Real-Time Strategy Telemetry Protected

Exact execution levels, Trailing Stops, and live bot signals are reserved for PRO members.

UNLOCK LIVE RADAR ⚡

📖 Intelligence Summary

Cue Biopharma, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of immunotherapies to treat cancer and autoimmune diseases. Its products include CUE-400 series (autoimmune diseases), CUE-500 series (targeted cell depletion), and CUE-100 series (Oncology). The company was founded by Ronald D. Seidel III, Steven Almo, and Rodolfo…

NEXT UPCOMING PREDICTIVE SIGNAL
STRONG BUY / TARGET +35%
🔓 REVEAL AI SIGNAL & TARGETS ↗